

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 34300

Title: Chemotherapy for hepatocellular carcinoma: The present and the future

Reviewer's code: 02860797

Reviewer's country: China

Science editor: Fang-Fang Ji

Date sent for review: 2017-05-01

Date reviewed: 2017-05-08

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This review focus on chemotherapy for Hepatocellular carcinoma systematically and summary most related clinical trials. 1.Since you think the effect of TACE combined with sorafenib is controversial, more available trials should be included, both positive and negative data should be discuss in detail. And for two trials you mentioned (SPACE, the trial from Kudo), please also show the data of overall survival. 2. The BRISK-PS showed overall survival between brivanib and sorafenib is the same, so could brivanib be an alternative choice as first line treatment? If not, discuss the reasons. 3.For the immunotherapy part, when you review the clinical trial of Nivolumab, the data should be precise. For example in their study they only get the data from 39 patients, so it should be 2/39 patients showed complete response? 4.please pay attetntion to some writing mistake, for example, 400ng\ml,p>0.001(SHARP trial).

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 34300

Title: Chemotherapy for hepatocellular carcinoma: The present and the future

Reviewer's code: 03656600

Reviewer's country: China

Science editor: Fang-Fang Ji

Date sent for review: 2017-05-01

Date reviewed: 2017-05-15

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Although some grammar problems, it is still a good review.